Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries.

ABSTRACT:

Background

Routinely, a 400-mg tablet of moxifloxacin is used in children with rifampicin-resistant TB (RR-TB), but it has very poor acceptability. We describe the acceptability of a 100-mg dispersible moxifloxacin among children and their caregivers in South Africa, India, and the Philippines.

Methods

This study is nested in a pharmacokinetics, safety, and acceptability trial of new formulations of clofazimine and moxifloxacin in children with RR-TB. Quantitative and qualitative data were collected at four time points over 24 weeks and were analysed descriptively and thematically.

Findings

Median age of participants (n = 36) was 4.9 years. Children and caregivers from all three countries preferred the dispersible 100-mg moxifloxacin to the routine 400-mg tablet due t

SUBMITTER: Suryavanshi N 

PROVIDER: S-EPMC12517267 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature